advanced search

Welcome: Guest

log in

0 items in basket Total: £0
$0 / €0

View Basket

Global Protein Therapeutics Market Analysis

Publication Date September 2007
Publisher RNCOS
Product Type Report
Pages 150
ISBN Number not applicable
Product Code RCS00223
Price

£1,230.00
approximately: $1,797 | €1,348

PDFBuy Now
PRINT £1,505 ($2,199 | €1,649)Buy Now
CD-ROM £1,505 ($2,199 | €1,649)Buy Now
Order above formats by FAXOrder by FAX

Summary

The latest market research report "Global Protein Therapeutics Market Analysis" by RNCOS provides an exhaustive view on the global protein therapeutics industry, examining and giving a detailed analysis of the various protein therapeutics used for disease prevention. The report discusses various aspects of the Protein Therapeutic Market, such as market size, area of applications and key geographical markets along with the drivers and restraints affecting the growth of each segment.

The Protein Therapeutic Market was valued in excess of US$ 57 Billion in 2006 and according to projections, it would grow at a CAGR 12.83% till 2010. The market is presently dominated by Monoclonal Antibodies and with double-digit growth projected for future, the segment is expected to bolster its dominant position. Insulin, Interferon Beta, G-CSF and coagulation factors are also exhibiting double-digit growth rates.

One of the biggest opportunity areas in the Protein Therapeutics Market will be in the field of Biogenerics, which is expected to create a multi-billion dollar market in future.

Key Findings

  • US is the largest market for therapeutic proteins in the world followed by Europe and Japan.
  • Insurance reimbursement is a major factor that decides the success of protein therapeutics.
  • Growth in protein therapeutic market will create new opportunities for the drug discovery Contract Research Organizations (CROs).
  • High expenditure on R&D and high rate of failure in phase-3 clinical trials remains a major challenge for the global protein therapeutics market.
  • Until recently, protein therapeutics faced little generic threat; however, this is likely to change in future with regulatory pathways for the approval of generics already present in Europe and Asia and to be introduced in US by 2009.

Key Issues and Facts Analyzed

  • Evaluation of past, current and future market trends.
  • Discussion about the major protein therapeutics and their markets.
  • Analysis of key geographical markets.
  • Analysis of various challenges and opportunities for the industry.
  • Future prospects of the various protein therapeutics segments.
  • Profile discussion of key players in this sector.

Key Players Analyzed

This section provides the overview, key facts, and financial information of prominent players in the global protein therapeutics market, such as Amgen, Genentech, Roche Group, Merck Serono S.A, Johnson & Johnson, Novo Nordisk A/S etc.

Research Methodology Used

Information Sources

Information has been sourced from credible sources including books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods

The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

For the purpose of this report, the following segments have been included in the Protein Therapeutics Market:
Monoclonal antibodies, EPO, Interferon's, Blood Clotting Factors, HGH, FSH, G-CSF and Insulin

Content

  • 1. Analyst View
  • 2. Global Therapeutic Proteins Market
    • 2.1 Market Analysis
      • 2.1.1 Market Size
      • 2.1.2 Therapeutic Proteins Market vs Pharmaceutical Market
      • 2.1.3 Market Segmentation
      • 2.1.4 Future Outlook (2007-2010)
  • 3. Industry Performance
    • 3.1 Monoclonal Antibodies (mAb)
      • 3.1.1 Market Size
      • 3.1.2 By Application
        • 3.1.2.1 Oncology Treatment
        • 3.1.2.2 Immunologic & Inflammatory Diseases Treatment
        • 3.1.2.3 Cardiovascular & Infectious Diseases Treatment
      • 3.1.3 Key Geographical Markets
        • 3.1.3.1 US
        • 3.1.3.2 Europe
        • 3.1.3.3 Japan
      • 3.1.4 Key Players & Drugs
      • 3.1.5 Industry Analysis
        • 3.1.5.1 Drivers
        • 3.1.5.2 Restraints
      • 3.1.6 Future Outlook (2007-2011)
    • 3.2 Erythropoietin (EPO)
      • 3.2.1 Market Size
        • 3.2.1.1 First Generation Erythropoietin
        • 3.2.1.2 Second Generation Erythropoietin
      • 3.2.2 By Application
        • 3.2.2.1 Renal Anemia Treatment
        • 3.2.2.2 Cancer Anemia Treatment
      • 3.2.3 Key Geographical Markets
        • 3.2.3.1 US
        • 3.2.3.2 Europe
        • 3.2.3.3 Japan
      • 3.2.4 Key Players & Drugs
        • 3.2.4.1 Erythropoietin Alpha
        • 3.2.4.2 Erythropoietin Beta
        • 3.2.4.3 Darbepoetin Alpha
      • 3.2.5 Industry Analysis
        • 3.2.5.1 Drivers
        • 3.2.5.2 Restraints
      • 3.2.6 Future Outlook (2007-2010)
    • 3.3 Insulin
      • 3.3.1 Market Size
      • 3.3.2 By Application
        • 3.3.2.1 Diabetes Treatment
      • 3.3.3 Key Geographical Markets
        • 3.3.3.1 India
        • 3.3.3.2 China
        • 3.3.3.3 US
        • 3.3.3.4 Russia
        • 3.3.3.5 Japan
        • 3.3.3.6 Germany
        • 3.3.3.7 Brazil
      • 3.3.4 Key Players & Drugs
      • 3.3.5 Industry Analysis
        • 3.3.5.1 Drivers
        • 3.3.5.2 Restraints
      • 3.3.6 Future Outlook (2007-2010)
    • 3.4 Interferon (IFN)
      • 3.4.1 Market Size
        • 3.4.1.1 Interferon Alpha
        • 3.4.1.1.1 By Application
        • 3.4.1.1.1.1 Hepatitis B Treatment
        • 3.4.1.1.1.2 Hepatitis C Treatment
        • 3.4.1.2 Interferon Beta
        • 3.4.1.2.1 By Application
        • 3.4.1.2.1.1 Multiple Sclerosis Treatment
      • 3.4.2 Key Geographical Markets
        • 3.4.2.1 US
        • 3.4.2.2 Europe
        • 3.4.2.2.1 Germany
        • 3.4.2.3 Japan
      • 3.4.3 Key Players & Drugs
        • 3.4.3.1 Interferon Alpha
        • 3.4.3.2 Interferon Beta
      • 3.4.4 Industry Analysis
        • 3.4.4.1 Drivers
        • 3.4.4.2 Restraints
      • 3.4.5 Future Outlook (2007-2011)
    • 3.5 Human Growth Hormone (HGH)
      • 3.5.1 Market Size
      • 3.5.2 By Application
        • 3.5.2.1 Pediatric Growth Hormone Deficiency Treatment
        • 3.5.2.2 Adult Growth Hormone Deficiency Treatment
      • 3.5.3 Key Geographical Markets
        • 3.5.3.1 US
        • 3.5.3.2 Europe & Japan
      • 3.5.4 Key Players & Drugs
      • 3.5.5 Industry Analysis
        • 3.5.5.1 Drivers
        • 3.5.5.2 Restraints
      • 3.5.6 Future Outlook (2007-2010)
    • 3.6 Blood Clotting Factor
      • 3.6.1 Market Size
        • 3.6.1.1 Recombinant Factor VIII
        • 3.6.1.2 Recombinant Factor VIIa
        • 3.6.1.3 Recombinant Factor IX
      • 3.6.2 Key Players & Drugs
      • 3.6.3 Industry Analysis
        • 3.6.3.1 Drivers
        • 3.6.3.2 Restraints
      • 3.6.4 Future Outlook (2007-2010)
    • 3.7 Follicle Stimulating Hormone (FSH)
      • 3.7.1 Market Size
      • 3.7.2 Key Players & Drugs
      • 3.7.3 Industry Analysis
        • 3.7.3.1 Drivers
        • 3.7.3.2 Restraints
      • 3.7.4 Future Outlook (2007-2010)
    • 3.8 Granulocyte Colony Stimulating Factor (G-CSF)
      • 3.8.1 Market Size
      • 3.8.2 Key Players & Drugs
      • 3.8.3 Industry Analysis
        • 3.8.3.1 Drivers
        • 3.8.3.2 Restraints
      • 3.8.4 Future Outlook (2007-2010)
  • 4. Industry Analysis
    • 4.1 Drivers
      • 4.1.1 Higher Efficacy than Traditional Drugs
      • 4.1.2 High Rate of Approval
      • 4.1.3 Ageing Population
      • 4.1.4 Healthcare Insurance
    • 4.2 Opportunities
      • 4.2.1 Biogenerics
      • 4.2.2 Contract Research
      • 4.2.3 Drug Delivery Devices
      • 4.2.4 Healthcare Insurance
      • 4.2.5 Drug Packaging
    • 4.3 Challenges
      • 4.3.1 Immunogenicity
      • 4.3.2 High R&D Cost
      • 4.3.3 High Price
      • 4.3.4 High Failure Rates in Phase-3 Clinical Trials
      • 4.3.5 Insurance Reimbursements
      • 4.3.6 Lack of Predictability in the Operating Environment
  • 5. Key Players
    • 5.1 Johnson & Johnson
    • 5.2 Biogen Idec Inc.
    • 5.3 Eli Lilly & Company
    • 5.4 Novo Nordisk A/S
    • 5.5 Sanofi-Aventis
    • 5.6 Roche Group
    • 5.7 Amgen Inc.
    • 5.8 Genentech, Inc.
    • 5.9 Merck Serono S.A
    • 5.10 Genzyme Corporation
  • List of Figures:
    • Figure 2-1: Global - Therapeutic Proteins Market (in Billion US$), 2005 & 2006E
    • Figure 2-2: Global - Comparison of Therapeutic Proteins Market to Pharmaceutical Market (in Billion US$), 2005 & 2006
    • Figure 2-3: Global - Therapeutic Proteins Market by Segment (%), 2006
    • Figure 2-4: Global - Forecast for Therapeutic Proteins Market (in Billion US$), 2007-2010
    • Figure 2-5: Global - Forecast for Therapeutic Proteins Market by Segment (%), 2010
    • Figure 3-1: Global - Monoclonal Antibodies Market (in Billion US$), 2004-2006E
    • Figure 3-2: Global - Monoclonal Antibodies Market in Cancer Treatment (in Billion US$), 2001, 2003 & 2006E
    • Figure 3-3: Global - Monoclonal Antibodies Market in Rheumatoid Arthritis Treatment (in Million US$), 2003-2005
    • Figure 3-4: Global - Monoclonal Antibodies Market in Cardiovascular & Infectious Diseases Treatment (in Million US$), 2004
    • Figure 3-5: US - Monoclonal Antibodies Market (in Billion US$), 2005 & 2006E
    • Figure 3-6: US - Forecast for Monoclonal Antibodies Market (in Billion US$), 2007-2012
    • Figure 3-7: Europe - Monoclonal Antibodies Market (in Billion US$), 2004-2006E
    • Figure 3-8: Europe - Forecast for Monoclonal Antibodies Market (in Billion US$), 2007-2011
    • Figure 3-9: Europe - Forecast for Monoclonal Antibodies Market by Application (%), 2011
    • Figure 3-10: Japan - Monoclonal Antibodies Market (in Billion JPY), 2003-2006E
    • Figure 3-11: Japan - Forecast for Monoclonal Antibodies Market (in Billion JPY), 2007-2011
    • Figure 3-12: Global - Share of Key Players in Monoclonal Antibodies Market (%), 2005
    • Figure 3-13: Global - Top Selling Monoclonal Antibodies (in Million US$), 2006
    • Figure 3-14: Global - Number of New Cancer Cases (in Million), 2000 & 2020F
    • Figure 3-15: Global - Forecast for Monoclonal Antibodies Market (in Billion US$), 2007-2011
    • Figure 3-16: Global - Forecast for Monoclonal Antibodies Market by Application (%), 2011
    • Figure 3-17: Global - Erythropoietin Market (in Billion US$), 2005 & 2006
    • Figure 3-18: Global - First Generation Erythropoietin Market (in Million US$), 2005 & 2006
    • Figure 3-19: Global - First Generation Erythropoietin Alpha Market (in Million US$), 2005 & 2006
    • Figure 3-20: Global - First Generation Erythropoietin Beta Market (in Million US$), 2005 & 2006
    • Figure 3-21: Global - Second Generation Erythropoietin Market (in Million US$), 2005 & 2006
    • Figure 3-22: Global - Number of Dialysis Patients (in Million), 2003-2006E
    • Figure 3-23: Global - Breakup of Dialysis Patients by Region (%), 2004
    • Figure 3-24: Europe - Number of Dialysis Patients Treated & Not Treated by Erythropoietin (in '000), 2004
    • Figure 3-25: Europe - Erythropoietin & Untapped Erythropoietin Market (in Million Euro), 2004
    • Figure 3-26: Global - Number of Cancer Patients (in Million), 2003-2006E
    • Figure 3-27: Global - Breakup of Cancer Patients by Region (%), 2004
    • Figure 3-28: Europe - Breakup of Cancer Therapy (%), 2004
    • Figure 3-29: Europe - Number of Chemotherapy Patients Treated & Not Treated by Erythropoietin (in '000), 2004
    • Figure 3-30: Europe - Erythropoietin & Untapped Erythropoietin Market (in Million Euro), 2004
    • Figure 3-31: US - Share in Global Erythropoietin Market (%), 2005
    • Figure 3-32: Europe - Erythropoietin Market (in Billion US$), 2003-2006E
    • Figure 3-33: Europe - Forecast for Erythropoietin Market (in Billion US$), 2007-2011
    • Figure 3-34: Europe - Erythropoietin Market in Renal Anemia Treatment (in Million US$), 2004-2006E
    • Figure 3-35: Europe - Forecast for Erythropoietin Market in Renal Anemia Treatment (in Million US$), 2007-2011
    • Figure 3-36: Europe - Erythropoietin Market in Oncology Treatment (in Million US$), 2004-2006E
    • Figure 3-37: Europe - Forecast for Erythropoietin Market in Oncology Treatment (in Million US$), 2007-2011
    • Figure 3-38: Europe - First Generation Erythropoietin Patent* Expiry by Major Country
    • Figure 3-39: Japan - Erythropoietin Market (in Billion JPY), 2003-2006E
    • Figure 3-40: Global - Forecast for Erythropoietin Market (in Billion US$), 2007-2010
    • Figure 3-41: Europe - Forecast for Share of Oncology & Renal Anemia in Erythropoietin Market (%), 2016
    • Figure 3-42: Global - Insulin Market (in Billion US$), 2005 & 2006
    • Figure 3-43: India - Insulin Market (in Million US$), 2004-2007E
    • Figure 3-44: India - Share of Key Players in Insulin Market (%), 2004
    • Figure 3-45: China - Insulin Market (in Million US$), 2006-2009E
    • Figure 3-46: China - Share of Key Players in Insulin Market (%), 2005
    • Figure 3-47: US - Insulin Market (in Billion US$), 2002-2006E
    • Figure 3-48: US - Share of Key Players in Insulin Market (%), 2005
    • Figure 3-49: Russia - Insulin Market (in Million US$), 2005-2008E
    • Figure 3-50: Russia - Share of Key Players in Insulin Market (%), 2005
    • Figure 3-51: Russia - Insulin Market by Channel of Sales (%), 2005
    • Figure 3-52: Japan - Insulin Market (in Million US$), 2005-2008E
    • Figure 3-53: Japan - Share of Key Players in Insulin Market (%), 2006
    • Figure 3-54: Germany - Share of Insulin in Genetically Manufactured Pharmaceuticals Market (%), 2005
    • Figure 3-55: Brazil - Insulin Market (in Million US$), 2000, 2006 & 2010F
    • Figure 3-56: Global - Share of Key Players in Insulin Market (%), Q1 2005
    • Figure 3-57: Global - Share of Novo Nordisk in Major Insulin Markets (%), 2006
    • Figure 3-58: Global - Share of Insulin Market by Brand (%), 2006*
    • Figure 3-59: Global - Number of Diabetic Patients (in Million), 2006 & 2025F
    • Figure 3-60: Global - Forecast for Insulin Market (in Billion US$), 2007-2010
    • Figure 3-61: Global - Interferon Market (in Billion US$), 2005 & 2006
    • Figure 3-62: Global - Share of Interferon Market by Segment (%), 2006
    • Figure 3-63: Global - Interferon Alpha Market (in Billion US$), 2005 & 2006
    • Figure 3-64: Global - Forecast for Hepatitis B Treatment Market (in Billion US$), 2010-2015
    • Figure 3-65: Global - Hepatitis C Treatment Market (in Billion US$), 2005 & 2006
    • Figure 3-66: Global - Forecast for Hepatitis C Treatment Market (in Billion US$), 2007-2015
    • Figure 3-67: Global - Forecast for Share of Interferon in Hepatitis C Treatment Market (%), 2015
    • Figure 3-68: Global - Interferon Beta Market (in Billion US$), 2005 & 2006
    • Figure 3-69: Global - Multiple Sclerosis Treatment Market (in Billion US$), 2006 & 2016F
    • Figure 3-70: US - Interferon Market (in Billion US$), 2006*
    • Figure 3-71: Europe - Interferon Market (in Million US$), 2004
    • Figure 3-72: Germany - Interferon Market (in Million Euro), 2005
    • Figure 3-73: Japan - Interferon Market (in Billion JPY), 2004-2006E
    • Figure 3-74: Global - Forecast for Interferon Market (in Billion US$), 2007-2011
    • Figure 3-75: Global - Human Growth Hormone Market (in Billion US$), 2005 & 2006
    • Figure 3-76: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (in '000), 2005
    • Figure 3-77: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature (%), 2006
    • Figure 3-78: Global - Adult Growth Hormone Deficiency Market (in Million US$), 2006
    • Figure 3-79: Global - Breakup of Human Growth Hormone Market by Region (%), 2003
    • Figure 3-80: US - Human Growth Hormone Market (in Million US$), 2003, 2005E & 2006E
    • Figure 3-81: Japan & Europe - Human Growth Hormone Market (in Million US$), 2003
    • Figure 3-82: Global - Share of Key Players in Human Growth Hormone Market (%), 2006
    • Figure 3-83: Global - Forecast for Human Growth Hormone Market (in Billion US$), 2007-2010
    • Figure 3-84: Global - Blood Clotting Factor Market (in Billion US$), 2005 & 2006E
    • Figure 3-85: Global - Share of Blood Clotting Factor Market by Segment (%), 2006
    • Figure 3-86: Global - Share of Key Players in Blood Clotting Factor Market (%), 2006
    • Figure 3-87: Global - Forecast for Blood Clotting Factor Market (in Billion US$), 2007-2010
    • Figure 3-88: Global - Recombinant Follicle Stimulating Hormone Market (in Billion US$). 2005 & 2006
    • Figure 3-89: Global - Forecast for Recombinant Follicle Stimulating Hormone Market (in Billion US$), 2007-2010
    • Figure 3-90: Global - Granulocyte Colony Stimulating Factor Market (in Billion US$), June 2005 & June 2006
    • Figure 3-91: Global - Breakup of Granulocyte Colony Stimulating Factor Market by Region (%), 2006
    • Figure 3-92: Global - Share of Granulocyte Colony Stimulating Factor Market by Brand (%), 2006*
    • Figure 3-93: Global - Forecast for Granulocyte Colony Stimulating Factor Market (in Billion US$), 2007-2010
    • Figure 4-1: Global - Approval Rate for Biopharmaceuticals & Conventional Pharmaceuticals (%)
    • Figure 4-2: Global - Population in Age Group of 65 Years & Above by Region (%), 2000, 2015F & 2030F
    • Figure 4-3: US & EU - Forecast for Biogeneric Market by Segment (in Million US$), 2010
    • Figure 4-4: Global - Contract Research Organization Market (in Billion US$), 2006 & 2010F
    • Figure 4-5: Global - Forecast for Drug Delivery Market (in Billion US$), 2007-2009
    • Figure 4-6: US - Number of Uninsured People (in Million), 2005 & 2006E
    • Figure 4-7: Global - Comparison of Annual Cost of Biotech Drugs to Traditional Drugs (in US$), 2006
    • Figure 4-8: Global - Failure Rate in Phase-3 Clinical Trials of Biotech & Traditional Drugs (%)
  • List of Tables:
    • Table 3-1: Global - Key Players & Drugs in Erythropoietin Alpha Market by Sale (in Million US$), 2006
    • Table 3-2: Global - Key Players & Drugs in Erythropoietin Beta Market by Sale (in Million CHF), 2006
    • Table 3-3: Global - Key Players & Drugs in Darbepoetin Alpha Market by Sale (in Million US$), 2006
    • Table 3-4: India - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-5: India - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 3-6: China - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-7: China - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 3-8: US - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-9: US - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 3-10: Russia - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-11: Russia - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 3-12: Japan - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-13: Japan - Forecast for Diabetic Patients in 20-79 Age Group (in '000), 2025
    • Table 3-14: Germany - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-15: Germany - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 3-16: Brazil - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 3-17: Brazil - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 3-18: Global - Key Players & Drugs in Interferon Alpha Market by Sale (in Million US$), 2006
    • Table 3-19: Global - Key Players & Drugs in Interferon Beta Market by Sale (in Million US$), 2006
    • Table 3-20: Global - Key Players & Drugs in Human Growth Hormone Market by Sale (in Million US$), 2006
    • Table 3-21: Global - Key Players & Drugs in Blood Clotting Factor Market by Sale (in Million US$), 2006
    • Table 3-22: Global - Key Players & Drugs in Recombinant Follicle Stimulating Hormone Market by Sale (in Million US$), 2006
    • Table 4-1: US & Europe - Patent Expiry Dates for Recombinant Biologics
    • Table 5-1: Johnson & Johnson - Key Financials (in Million US$), 2004-2006
    • Table 5-2: Biogen Idec Inc. - Key Financials (in Million US$), 2004-2006
    • Table 5-3: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
    • Table 5-4: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
    • Table 5-5: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
    • Table 5-6: Roche Group - Key Financials (in Million CHF), 2004-2006
    • Table 5-7: Amgen, Inc. - Key Financials (in Million US$), 2004-2006
    • Table 5-8: Genentech, Inc. - Key Financials (in Million US$), 2004-2006
    • Table 5-9: Merck Serono S.A - Key Financials (in Million US$), 2003-2005
    • Table 5-10: Genzyme Corporation - Key Financials (in Million US$), 2004-2006

back to top

About this Product
Delivery Details

PDF:Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)
PRINT/CD-ROM:Despatched within 2 to 4 working days.

Ask a question about this product?

Need help finding the right product?

Related Products

Industry Events

Healthcare New Media PR and Marketing Conference

15 Jun 09 to 17 Jun 09
Phoenix, US
view summary >>

2nd Annual Global Generic Medicines Summit

27 Feb 08 to 28 Feb 08
London, UK
view summary >>

Intelligent comment on RBlog
#

Pharma & Healthcare

Customer Services

How To Buy
Formats & Delivery
Terms & Conditions
Account Options
Login/Register

call +44 (0) 20 7060 7474
or email us

Resources

Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories

Post it

Del.icio.us
StumbleUpon
Reddit

logo: AddThis